NCT04330625 2022-11-08Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)Duke UniversityPhase 1 Terminated1 enrolled
NCT04253223 2021-06-11A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to CopanlisibDuke UniversityPhase 1 Terminated1 enrolled